Actinium Pharmaceuticals is advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.Read more
Actinium Pharmaceuticals on Monday announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B at 50% of total of 150-patient, compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML (Acute Myeloid Leukemia).Read more
Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.Read more
Actinium Pharmaceuticals has appointed Cynthia Pussinen as Executive Vice President, Technical Operations and Supply Chain, who will also serve as a member of Actinium’s executive leadership team.Read more
@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
Actinium Pharmaceuticals and Astellas Pharma will work together to develop Actinium-225 Radio-Conjugates (ARCs) using Actinium Warhead Enabling (AWE) Platform Technology,Read more
A Phase 1 trial of Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia (AML) patients, will beRead more
Actinium Pharmaceuticals has applied an Investigational New Drug for Actimab-A combined with CLAG-M, for Acute Myeloid Leukemia, to the USFDA.Read more